Paraproteinemia

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 690 Experts worldwide ranked by ideXlab platform

Biagio Guarneri - One of the best experts on this subject based on the ideXlab platform.

Clive B. Archer - One of the best experts on this subject based on the ideXlab platform.

Keiya Ozawa - One of the best experts on this subject based on the ideXlab platform.

  • Paraproteinemia after hematopoietic stem cell transplantation
    Leukemia & Lymphoma, 2004
    Co-Authors: Takahiro Nagashima, Kazuo Muroi, Chizuru Kawanoyamamoto, Norio Komatsu, Keiya Ozawa
    Abstract:

    The frequency and clinical significance of Paraproteinemia in patients receiving hematopoietic stem cell (HSC) transplants were assessed. Of 66 patients with hematologic malignancies, excluding multiple myeloma who received an allogeneic or autologous HSC transplant, paraproteins were detected in 12 patients using immunoelectrophoresis. None of the patients showed Paraproteinemia before HSC transplantation. The class of paraproteins most commonly seen was IgG. In 9 of these 12 patients (75%), a paraprotein was detected continuously after HSC transplantation for an average duration of 464 days, while others demonstrated a transient appearance of the protein. Paraproteinemia after HSC transplantation was not related to the stem cell source, (allograft vs. autograft), age, gender, viral infection and graft-vs.-host disease (GVHD). None of the patients developed plasma cell dyscrasia after the appearance of the paraprotein, while 1 patient developed secondary acute lymphoblastic leukemia. These findings indicate that Paraproteinemia after HSC transplantation may be caused by an aberrant immune reconstitution after both allogeneic and autologous HSC transplantation. A long-term follow-up of patients with Paraproteinemia after HSC transplantation is needed to confirm this finding in a larger series of patients.

R. C. Ongley - One of the best experts on this subject based on the ideXlab platform.

  • Erythema elevatum diutinum associated with IgA Paraproteinemia successfully controlled with intermittent plasma exchange
    Archives of dermatology, 1996
    Co-Authors: R. K. P. Chow, W. B. Benny, R. L. Coupe, W. A. Dodd, R. C. Ongley
    Abstract:

    Background: We review the literature and report a case of refractory erythema elevatum diutinum associated with IgA Paraproteinemia that was successfully controlled with intermittent plasma exchange (PLEX). Observations: Typical lesions of erythema elevatum diutinum developed in a 72-year-old patient with IgA Paraproteinemia; the condition predictably flared whenever IgA levels reached a threshold of 8 g/L. After 8 years of unsuccessful treatment with various agents, we instituted a trial of PLEX during an acute flare. Following 6 exchanges over a period of 2 weeks, the IgA level decreased from 8 to 2 g/L and the skin lesions cleared. Three weeks later, new skin lesions developed and the IgA level had rebounded from 2 to just over 8 g/L. A second course of PLEX was administered, with excellent results, and a 3-month course of oral chlorambucil (2 mg/d) was initiated. The patient's condition remained in clinical remission for 10 months. Over the ensuing 9 years, she suffered 11 further flares, each of which was associated with IgA levels of 8 to 10 g/L and each responding dramatically to 3 to 5 PLEXs followed by a consolidative dose of intravenous cyclophosphamide (250-500 mg). Conclusion: We believe that PLEX may have an important role in the management of severe erythema elevatum diutinum associated with monoclonal Paraproteinemia refractory to other therapy. Arch Dermatol. 1996;132:1360-1364

Mario Vaccaro - One of the best experts on this subject based on the ideXlab platform.